Amplia Therapeutics Ltd (ASX:ATX) CEO Dr Chris Burns tells Proactive the company has received grant funding to undertake a research collaboration with Australia’s national science agency to develop topical formulations of its FAK inhibitors. Amplia will work with researchers at CSIRO to help develop formulations that could be applied topically to wounds and burns to aid healing and reduce scarring.
Amplia secures funding to assess AMP945 topical applications
